Page 14 - Be Limited News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Photo Credit: IANS IANSLive Hyderabad, April 24 (IANS) Hyderabad-based vaccine and pharmaceutical company Biological E. Limited (BE) announced on Saturday that its Covid-19 subunit vaccine candidate has received approval to begin Phase III clinical trials in India. To get full access of the story, click here to subscribe to IANS News Service © 2021 IANS India Private Limited. All Rights Reserved. The reproduction of the story/photograph in any form will be liable for legal action. For news, views and gossips, follow IANS at Twitter. Update: 24-April-2021

 E-Mail COLUMBUS, Ohio - A new SARS-CoV-2 vaccine candidate, developed by giving a key protein's gene a ride into the body while encased in a measles vaccine, has been shown to produce a strong immune response and prevent SARS-CoV-2 infection and lung disease in multiple animal studies. Scientists attribute the vaccine candidate's effectiveness to strategic production of the antigen to stimulate immunity: using a specific snippet of the coronavirus spike protein gene, and inserting it into a sweet spot in the measles vaccine genome to boost activation, or expression, of the gene that makes t...

The News Scroll 29 December 2020   Last Updated at 4:59 pm | Source: PTI CEPI partners with Biological E.Ltd for COVID-19 vaccine candidate Outlook December 29, 2020 16:59 IST CEPI partners with Biological E.Ltd for COVID-19 vaccine candidate outlookindia.com 1970-01-01T05:30:00+0530 Hyderabad, Dec 29 (PTI) Norway-headquartered CEPI, (Coalition for Epidemic Preparedness Innovations) and city- based Biological E. Limited on Tuesday announced a collaboration to advance the development and manufacture of the latter''s COVID-19 subunit vaccine candidate. CEPI will...

IFC Supports BioE to expand access to low-cost vaccines in developing countries Format E-mail: mdesouza1@ifc.org New Delhi, India, 17 December, 2020—An investment in one of India’s top vaccine manufacturers, Biological E Limited (BioE), will expand access to low-cost vaccines for children in developing countries and help increase production of a COVID-19 vaccine when developed, a key step in saving lives and restarting economies. IFC, a member of the World Bank Group, is providing a senior loan of up to $30 million to BioE to support the Hyderabad-based company’s expansion of its range ...

Thursday, 17 December 2020, 7:23 pm An investment in one of India’s top vaccine manufacturers, Biological E Limited (BioE), will expand access to low-cost vaccines for children in developing countries and help increase production of a COVID-19 vaccine when developed, a key step in saving lives and restarting economies. IFC, a member of the World Bank Group, is providing a senior loan of up to $30 million to BioE to support the Hyderabad-based company’s expansion of its range of low-priced, generic vaccines for routine immunization of children. Furthermore, the financing package aims to s...